These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15723219)

  • 1. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
    Kishida O; Miyazaki Y; Murayama Y; Ogasa M; Miyazaki T; Yamamoto T; Watabe K; Tsutsui S; Kiyohara T; Shimomura I; Shinomura Y
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):584-94. PubMed ID: 15723219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
    Kishida O; Miyazaki Y; Murayama Y; Ogasa M; Miyazaki T; Yamamoto T; Watabe K; Tsutsui S; Kiyohara T; Shimomura I; Shinomura Y
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):393-403. PubMed ID: 15723263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
    Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells.
    Rodrigues S; Attoub S; Nguyen QD; Bruyneel E; Rodrigue CM; Westley BR; May FE; Thim L; Mareel M; Emami S; Gespach C
    Oncogene; 2003 Jul; 22(29):4488-97. PubMed ID: 12881705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autocrine ligands for the epidermal growth factor receptor mediate interleukin-8 release from bronchial epithelial cells in response to cigarette smoke.
    Richter A; O'Donnell RA; Powell RM; Sanders MW; Holgate ST; Djukanović R; Davies DE
    Am J Respir Cell Mol Biol; 2002 Jul; 27(1):85-90. PubMed ID: 12091250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteinizing hormone signaling in preovulatory follicles involves early activation of the epidermal growth factor receptor pathway.
    Panigone S; Hsieh M; Fu M; Persani L; Conti M
    Mol Endocrinol; 2008 Apr; 22(4):924-36. PubMed ID: 18187604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
    Yasumoto K; Yamada T; Kawashima A; Wang W; Li Q; Donev IS; Tacheuchi S; Mouri H; Yamashita K; Ohtsubo K; Yano S
    Clin Cancer Res; 2011 Jun; 17(11):3619-30. PubMed ID: 21482691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Yang Z; Bagheri-Yarmand R; Wang RA; Adam L; Papadimitrakopoulou VV; Clayman GL; El-Naggar A; Lotan R; Barnes CJ; Hong WK; Kumar R
    Clin Cancer Res; 2004 Jan; 10(2):658-67. PubMed ID: 14760089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
    Azzariti A; Xu JM; Porcelli L; Paradiso A
    Biochem Pharmacol; 2004 Jul; 68(1):135-44. PubMed ID: 15183125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
    Wakeling AE; Guy SP; Woodburn JR; Ashton SE; Curry BJ; Barker AJ; Gibson KH
    Cancer Res; 2002 Oct; 62(20):5749-54. PubMed ID: 12384534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.
    Li J; Kleeff J; Giese N; Büchler MW; Korc M; Friess H
    Int J Oncol; 2004 Jul; 25(1):203-10. PubMed ID: 15202007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
    FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor.
    Ogunwobi OO; Beales IL
    Br J Biomed Sci; 2008; 65(3):121-7. PubMed ID: 18986098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.